A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies-Reference-Cited by-同舟云学术

A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies

Published:2021-02-27 Issue:6 Volume:10 Page:1944-1954
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Trivedi Neel D.¹,Armstrong Samantha¹,Wang Hongkun¹,Hartley Marion²^ORCID,Deeken John³,Ruth He A.¹,Subramaniam Deepa¹,Melville Heather¹,Albanese Chris¹,Marshall John L.¹^ORCID,Hwang Jimmy⁴,Pishvaian Michael J.⁵^ORCID

Affiliation:

1. Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington DC USA

2. The Ruesch Center for the Cure of Gastrointestinal Cancers Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington DC USA

3. Inova Schar Cancer InstituteInova Health System Falls Church VA USA

4. Levine Cancer InstituteCarolinas HealthCare System Charlotte NC USA

5. Department of Oncology Johns Hopkins University School of MedicineSKCC Washington DC USA

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3672

Reference35 articles.